• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Grifols S.A.

    4/9/25 3:30:22 PM ET
    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRFS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    Grifols SA

    (Name of Issuer)


    Class B shares

    (Title of Class of Securities)


    398438408

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    398438408


    1Names of Reporting Persons

    BRANDES INVESTMENT PARTNERS, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    7Sole Dispositive Power

    8Shared Dispositive Power

    18,761,824.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    18,761,824.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    16.4 %
    12Type of Reporting Person (See Instructions)

    IA, PN

    Comment for Type of Reporting Person:  Shared Dispositive Power 18,761,824 ORDs and 24,178,118 ADRs Aggregate Amount Beneficially Owned by Each Reporting Person 18,761,824 ORDs and 24,178,118 ADRs


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Grifols SA
    (b)Address of issuer's principal executive offices:

    2410 Grifols Way, Los Angeles, CALIFORNIA, 90032-3514.
    Item 2. 
    (a)Name of person filing:

    Brandes Investment Partners, L.P.
    (b)Address or principal business office or, if none, residence:

    4275 Executive Square, 5th Floor, La Jolla, CA 92037
    (c)Citizenship:

    Delaware
    (d)Title of class of securities:

    Class B shares
    (e)CUSIP No.:

    398438408
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    18,761,824 ORDs and 24,178,118 ADRs
    (b)Percent of class:

    16.43 %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    18,761,824 ORDs and 24,178,118 ADRs

    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    N/A
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    N/A
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    N/A
    Item 9.Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.


    N/A

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    BRANDES INVESTMENT PARTNERS, LP
     
    Signature:/s/ Glenn Carlson
    Name/Title:Executive Director
    Date:04/04/2025
    Get the next $GRFS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRFS

    DatePrice TargetRatingAnalyst
    2/12/2025Overweight
    Morgan Stanley
    3/12/2024Hold → Sell
    Deutsche Bank
    4/12/2023Equal-Weight → Overweight
    Morgan Stanley
    3/3/2023Overweight → Equal-Weight
    Morgan Stanley
    2/16/2023Underweight → Equal Weight
    Barclays
    1/18/2023Hold → Buy
    Jefferies
    4/8/2022Equal-Weight
    Morgan Stanley
    11/5/2021Buy → Hold
    Deutsche Bank
    More analyst ratings

    $GRFS
    SEC Filings

    See more
    • SEC Form 6-K filed by Grifols S.A.

      6-K - Grifols SA (0001438569) (Filer)

      6/5/25 3:58:16 PM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Grifols S.A.

      6-K - Grifols SA (0001438569) (Filer)

      5/12/25 12:36:55 PM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Grifols S.A.

      6-K - Grifols SA (0001438569) (Filer)

      5/6/25 12:01:34 PM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRFS
    Financials

    Live finance-specific insights

    See more
    • Grifols acquires its first plasma donation center in Canada

      BARCELONA, Spain, Jan. 4, 2022 /PRNewswire/ -- Grifols ((MCE: GRF, MCE: GRF.P, NASDAQ:GRFS), a global healthcare company and one of world's top producers of plasma-derived medicines, today announced the acquisition of its first donation center in Canada as part of the company's commitment to increase the availability of lifesaving plasma medicines in the country. In a share-purchase agreement, Grifols Canada Therapeutics Inc has acquired Prometic Plasma Resources Inc's (PPR) donation center in Winnipeg from Kedrion for USD 4 million in cash. With the center, Grifols furthers

      1/4/22 12:30:00 PM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRFS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $GRFS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13G/A filed by Grifols S.A.

      SC 13G/A - Grifols SA (0001438569) (Subject)

      11/14/24 11:46:03 AM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Grifols S.A. (Amendment)

      SC 13G/A - Grifols SA (0001438569) (Subject)

      2/9/24 2:45:34 PM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Grifols S.A.

      SC 13G - Grifols SA (0001438569) (Subject)

      2/9/24 2:21:17 PM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley resumed coverage on Grifols, S.A.

      Morgan Stanley resumed coverage of Grifols, S.A. with a rating of Overweight

      2/12/25 9:09:54 AM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Grifols, S.A. downgraded by Deutsche Bank

      Deutsche Bank downgraded Grifols, S.A. from Hold to Sell

      3/12/24 1:36:28 PM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Grifols, S.A. upgraded by Morgan Stanley

      Morgan Stanley upgraded Grifols, S.A. from Equal-Weight to Overweight

      4/12/23 8:07:28 AM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRFS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting

      Believes Board Leadership Continuity and Continued Management Focus and Execution Will Drive Long-Term Shareholder Value Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 3% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ:GRFS) class A shares, today announced that it sent a letter to the Grifols Board of Directors (the "Board") expressing Mason's support for the Company's recommended slate of director candidates for election at the Ordinary General Shareholders' Meeting to be held on June 4 and 5, 2025. The full text of the letter follows: May 28, 2025 Grifols, S.A. Avinguda de la Generalitat 152-158 0

      5/30/25 4:05:00 PM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson's Disease

      ‘Chronos-PD' is looking for biological signals that could indicate increased chance of developing Parkinson's disease (PD) years before symptoms appear, leading to new diagnostic tools and disease-modifying therapiesPart of broad Grifols program to find disease-revealing clues in more than 100 million proprietary plasma samples connected to real-world data on thousands of disease states in many therapeutic areasCutting-edge use of AI and proteomics technology paired with real-world evidence underscores the company's ongoing commitment to bold scientific innovation to benefit patients BARCELONA, Spain, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Grifols ((MCE: GRF, MCE: GRF.P, NASDAQ:GRFS), a global

      1/14/25 6:00:00 AM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mason Capital Management Sends Letter to Spanish National Securities Market Commission Regarding Lack of Transparency by Grifols

      Urges Improved Disclosure Around Key Issues for the Benefit of Grifols Shareholders Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.5% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ:GRFS) class A shares, today sent a letter to the Spanish National Securities Market Commission (the "CNMV") calling the CNMV's attention to the troubling and value destructive lack of transparency by Grifols and its Board of Directors (the "Board"). In the letter, Mason urges the CNMV to consider the benefits to all Grifols shareholders from improved disclosure around several key issues, including: Related-party transac

      1/13/25 10:00:00 AM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRFS
    Leadership Updates

    Live Leadership Updates

    See more
    • Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

      Sends Letter to Board Detailing Board's Conflicts of Interest and History of Poor Capital Allocation Expresses Urgent Need for Independent Directors and Proper Oversight to Unlock Value Believes Rumored Brookfield Transaction Substantially Undervalues Grifols Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ:GRFS) class A shares, today sent a letter to the Grifols Board of Directors (the "Board"). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241107873955/en/Historical Forward EV/EBITDA Multip

      11/8/24 3:54:00 PM ET
      $GRFS
      $SYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023

      BARCELONA, Spain, April 18, 2023 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people's health and well-being for more than 110 years, today announces the filling of its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, with the United States Securities and Exchange Commission ("SEC"). Grifols' annual report under Form 20-F is a critical component of the company's commitment to transparency and accountability. The filing of the annual report provides investors with an overview of the company's governance practices, including informa

      4/18/23 10:30:00 AM ET
      $GRF
      $GRFS
      Finance/Investors Services
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson

      Victor Grifols Roura, who devoted 50 years to building Grifols in senior roles including CEO for 30 years, retires as non-executive Chairperson and is designated as Chairperson of Honor in recognition of his numerous contributionsSteven F. Mayer, former Co-Head of Global Private Equity and Chairman of the Investment Committee of private investment firm Cerberus Capital Management, L.P., with more than 10 years serving as a Grifols independent board member, is appointed as Executive ChairpersonChanges further evidence of the Board of Directors' focus on strategic objectives, operational excellence, and deleveraging balance sheetBARCELONA, Spain, Oct. 3, 2022 /PRNewswire/ -- Grifols (MCE: GRF)

      10/3/22 12:52:00 PM ET
      $GRFS
      Biotechnology: Pharmaceutical Preparations
      Health Care